Chronological analysis of the gut microbiome for efficacy of atezolizumab‐based immunotherapy in non‐small cell lung cancer: Protocol for a multicenter prospective observational study

BACKGROUND: Cancer immunotherapy with immune checkpoint inhibitors (ICIs) is an innovative treatment for non‐small cell lung cancer (NSCLC). Recently, the specific composition of the gut microbiome before initiation of cancer immunotherapy has been highlighted as a predictive biomarker in patients u...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Fumihiro, Miura, Naoko, Tagawa, Tetsuzo, Tsukamoto, Shuichi, Okamoto, Tatsuro, Yamazaki, Koji, Hamatake, Motoharu, Takeo, Sadanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527175/
https://www.ncbi.nlm.nih.gov/pubmed/36063818
http://dx.doi.org/10.1111/1759-7714.14640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527175/
https://www.ncbi.nlm.nih.gov/pubmed/36063818
http://dx.doi.org/10.1111/1759-7714.14640

Ejemplares similares